Trials / Completed
CompletedNCT00642538
A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus
A Phase 1, Repeated Single-Dose, Double Blind, Randomized, Five Treatment Controlled Safety and Pharmacological Response Evaluation Trial of MKC253 Inhalation Powder in Adult Male and Postmenopausal Female Subjects With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Mannkind Corporation · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
20 eligible subjects will be enrolled into the treatment phase of the trial.
Detailed description
Trial objectives are to determine the safety \& pharmacological response of MKC253 Inhalation Powder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MKC253 Inhalation Powder | Inhalation Powder, prandial |
| DRUG | Technosphere Inhalation Powder | Inhalation Powder, prandial |
| DRUG | subcutaneous injection | 10µg Exenatide, prandial |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2008-09-01
- Completion
- 2008-09-01
- First posted
- 2008-03-25
- Last updated
- 2012-06-14
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00642538. Inclusion in this directory is not an endorsement.